Filing Flows › Comparisons › OVID vs XBIO
Ovid Therapeutics vs Xenetic Biosciences: OVID and XBIO compared
Ovid Therapeutics is the larger company: $733K of revenue in its latest quarter (Q2 2026) against $661K for Xenetic Biosciences (Q2 2026). Xenetic Biosciences is growing faster (+12% against -88% a year earlier).
Where the money goes: OVID and XBIO
Ovid Therapeutics (OVID) · Q2 2026
Ovid Therapeutics, Q2 2026: revenue $733K (-88% year over year), net loss $15.0M, operating cash flow −$17.6M. The chart follows the revenue to costs, profit and cash.
Xenetic Biosciences (XBIO) · Q2 2026
Xenetic Biosciences, Q2 2026: revenue $661K (+12% year over year), operating margin -147.1%, net loss $930K, operating cash flow −$875K. The chart follows the revenue to costs, profit and cash.
| Ovid Therapeutics (OVID) | Xenetic Biosciences (XBIO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $733K | $661K |
| Revenue growth, Y/Y | -88% | +12% |
| Operating margin | n/m | -147.1% |
| Net earnings | −$15.0M | −$930K |
| Net margin | — | -140.7% |
| Operating cash flow | −$17.6M | −$875K |
Questions
Which is bigger, Ovid Therapeutics or Xenetic Biosciences?
Ovid Therapeutics is the larger company: $733K of revenue in its latest quarter (Q2 2026) against $661K for Xenetic Biosciences (Q2 2026).
Is Ovid Therapeutics or Xenetic Biosciences growing faster?
Xenetic Biosciences is growing faster (+12% against -88% a year earlier).
More: Ovid Therapeutics earnings · how Ovid Therapeutics makes money · Xenetic Biosciences earnings · how Xenetic Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 6, 2026). Fiscal quarters can end on different dates. Not investment advice.